New updates have been reported about ZipBio.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ZipBio has signed an exclusive licensing agreement granting MeiraGTx rights to its first-in-class, AI-designed therapies for Geographic Atrophy that act on the complement pathway, marking a significant monetization and partnering milestone for the private biotech. The deal links ZipBio’s COMPACT generative AI protein design platform with MeiraGTx’s AAV vector, clinical development, and in-house genetic medicine manufacturing capabilities, with ZipBio eligible for an upfront payment plus development, regulatory, and commercial milestones, as well as royalties, though specific financial terms were not disclosed.
The transaction allows ZipBio to offload clinical and manufacturing execution risk in ophthalmology while it reallocates capital and internal resources toward its wholly owned immunology and cardiovascular programs, where the company is building a pipeline of multi-specific, logic-gated “Zip” protein therapeutics against historically hard-to-drug targets. CEO Roee Farber framed the alliance as a way to accelerate delivery of AI-designed therapies to a large unmet-need population in Geographic Atrophy, while reinforcing ZipBio’s strategy of using COMPACT to generate differentiated biologics across high-impact diseases, underscoring the broader trend of AI-enabled biologics becoming a key component of modern drug discovery and partnering models.